TPT‐004, a Next‐Generation Inhibitor of Tryptophan Hydroxylase, Ameliorates Pulmonary Arterial Hypertension in Rats
Open Access
- 21 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e034240
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase InhibitorsJournal of Medicinal Chemistry, 2023
- Serotonin and Pulmonary Hypertension; Sex and Drugs and ROCK and Rho2022
- Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase InhibitorsJournal of Medicinal Chemistry, 2022
- A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)Pulmonary Circulation, 2022
- Inhibition of serotonin synthesis: A novel therapeutic paradigmPharmacology & Therapeutics, 2020
- Ginsenoside Rg1 improves lipopolysaccharide-induced acute lung injury by inhibiting inflammatory responses and modulating infiltration of M2 macrophagesInternational Immunopharmacology, 2015